Media Articles Related to Boniva Injection (Ibandronic Acid)
Osteoporosis in Patients Undergoing Lumbar Fusion
Source: Medscape General Surgery Headlines [2016.11.23]
A new study examines the incidence of undiagnosed osteoporosis of the lumbar spine among patients undergoing transforaminal lumbar interbody fusion. How were these cases identified?
Phase 3 Bridge study showed romosozumab significantly increased bone mineral density in men with osteoporosis
Source: Arthritis / Rheumatology News From Medical News Today [2016.11.15]
UCB and Amgen have announced results from the Phase 3 BRIDGE study showing that in men with osteoporosis, the investigational agent romosozumab resulted in significant bone mineral density (BMD)...
Research reveals how novel osteoporosis drug increases bone mass
Source: Bones / Orthopedics News From Medical News Today [2016.10.20]
Abaloparatide, a selective activator of the parathyroid hormone receptor, has recently been shown to reduce fractures in postmenopausal women with osteoporosis.
Heavy marijuana use may raise risk of osteoporosis, bone fractures
Source: Smoking / Quit Smoking News From Medical News Today [2016.10.13]
People who regularly smoke large amounts of marijuana may have lower bone density, increasing their later-life risk of osteoporosis and bone fractures.
What Is Osteoporosis? Treatment, Symptoms, Medication
Source: MedicineNet Lactose Intolerance Specialty [2016.07.28]
Title: What Is Osteoporosis? Treatment, Symptoms, Medication
Created: 4/23/2009 12:00:00 AM
Last Editorial Review: 7/28/2016 12:00:00 AM
Published Studies Related to Boniva Injection (Ibandronic Acid)
Long-term safety of intravenous ibandronic acid for up to 4 years in metastatic breast cancer: an open-label trial. 
BACKGROUND AND OBJECTIVE: Despite their widespread use in metastatic bone disease, some bisphosphonate drugs are associated with adverse events (AEs), particularly renal toxicity, adding to treatment burdens and increasing healthcare costs. Ibandronic acid is a single-nitrogen bisphosphonate with high efficacy against bone events and metastatic bone pain, and a renal safety profile compar- able to that of placebo. In this study, the safety of ibandronic acid was examined over a period of 4 years... CONCLUSION: This 96-week open-label safety extension of a phase III, placebo-controlled trial demonstrates that long-term use of intravenous ibandronic acid is well tolerated.
Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). [2005.12]
CONCLUSIONS: Significantly more women with postmenopausal osteoporosis preferred once-monthly ibandronate therapy to once-weekly alendronate therapy, and found the once-monthly regimen to be more convenient. Ease of following a treatment regimen for a long time was the most common reason given for the patients' preferences.
Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone
metastases from breast cancer: a randomised, open label, non-inferiority phase 3
the treatment of metastatic breast cancer to bone... INTERPRETATION: Our results suggest that zoledronic acid is preferable to
Bioequivalence study of two formulations of ibandronic acid 150-mg film-coated
tablets in healthy volunteers under fasting conditions: a randomized, open-label,
three-way, reference-replicated crossover study. 
Bonviva(®)... CONCLUSIONS: Test formulation of ibandronic acid is bioequivalent in rate and
Renal function changes and NHS resource use in breast cancer patients with metastatic bone disease treated with IV zoledronic acid or oral ibandronic acid: a four-centre non-interventional study. [2010.03]
AIMS: To describe renal function monitoring practice in patients with metastatic bone disease (MBD) treated with IV zoledronic acid (ZA) and oral ibandronic acid (IA), the management pathways and NHS hospital resources used... CONCLUSION: Although limited by retrospective design, these results demonstrate that in many patients, CrCl is not calculated before or during treatment with bisphosphonates. Renal function deteriorated in many patients during therapy. In view of these effects, practice should be reviewed to ensure appropriate dosing.
Clinical Trials Related to Boniva Injection (Ibandronic Acid)
Bioequivalence Study of Ibandronate Sodium Tablets 150 mg Under Fasting Condition [Completed]
This is an open label, randomised, balanced, two-treatment, two-period, two-sequence,
crossover, oral bioequivalence study.
PTH & Ibandronate Combination Study (PICS) [Completed]
This study will test in several innovative ways, several different combinations of PTH and
oral monthly ibandronate for the treatment of osteoporosis in postmenopausal women. The
intension is to provide other options for treatment than the current standard 2 year course
of drug therapy. These options may lead to treatment where the two years of therapy are
spread over several years.
A Study Comparing Monthly Bonviva (Ibandronate) and Weekly Risedronate in Women With Post-Menopausal Osteoporosis. [Completed]
This 2-sequence crossover study will evaluate patient reported preference for once-monthly
ibandronate (150 mg orally) as opposed to once-weekly risedronate (35 mg orally).
Participants with post-menopausal osteoporosis will be randomized to receive one product
for three months (12 weeks). They will then cross over to receive the other treatment for
three months (12 weeks). The anticipated time on study treatment is 6 months (plus a 15-day
follow up period), and the target sample size is 100-500 individuals.
BONVIVA(Ibandronate) PMS(Post-marketing Surveillance ) [Completed]
Study Comparing Ibandronate Versus Placebo in Hip Osteonecrosis [Recruiting]
Aseptic osteonecrosis of the hip (AOH) concern 1 Swiss young adult to 1000 (30-40 years
old). They are responsible to a severe joint destruction and in the majority of cases a
joint replacement. To the hip, we can distinguish 4 stages of osteonecrosis according to
Ficat: 1, 2, 3, 4. Stage 3 and 4 AOH management are unanimous surgical. But management of
stage 1 and 2 are unclear. Bisphophonates are mainly used for bone and osteoporosis
diseases. They decrease the bone turn over, and the risk of fracture. They also decrease the
bone marrow oedema and the pain associated to this oedema. Ibandronate is a bisphosphonate
with a rapid effect, a short half-life, easy to manage, and with few side effects. We
designed a double-blind prospective randomized trial aiming to evaluate the efficacy of an
infusion of ibandronate versus placebo on pain and AOH progression in patients with stage 1
and 2 AOH. Our hypothesis is that there will be a pain reduction >=20 mm on the VAS scale
(SD 10mm) in the ibandronate group versus placebo, and a non radiological progression in the